Pneumococcal Infections

22
Pipeline Programs
3
Companies
36
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
5
0
12
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
3100%
+ 21 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
18 programs
1
1
4
11
1
ProDiax-23Phase 41 trial
Rotarix™Phase 31 trial
V114Phase 31 trial
V114Phase 31 trial
V114Phase 31 trial
+13 more programs
Active Trials
NCT03848065Completed133Est. Jun 2020
NCT02531373Completed338Est. Apr 2017
NCT04923035Unknown1,010Est. Dec 2024
+19 more trials
Pfizer
PfizerNEW YORK, NY
5 programs
1
1
1
13 valent Pneumococcal Conjugate VaccinePhase 3Vaccine4 trials
MultivalentPhase 25 trials
PneumovaxPhase 1/21 trial
An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency DepartmentN/A1 trial
Immunization To Prevent Acute COPD ExacerbationsN/A1 trial
Active Trials
NCT01899365Completed1,475Est. Oct 2017
NCT03276754Terminated530Est. Jun 2022
NCT00137605Completed79Est. Oct 2007
+9 more trials
Sanofi
SanofiPARIS, France
1 program
1
Pneumococcal VaccinePhase 1Vaccine1 trial
Active Trials
NCT01444001Completed63Est. Aug 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.ProDiax-23
Pfizer13 valent Pneumococcal Conjugate Vaccine
Merck & Co.V114
Merck & Co.V114
Merck & Co.Rotarix™
Merck & Co.V114
Merck & Co.V114
Merck & Co.V114
Merck & Co.V114
Merck & Co.V114
Merck & Co.V114
Merck & Co.V114
Merck & Co.V114
Pfizer13 valent Pneumococcal Conjugate Vaccine
Pfizer13 valent Pneumococcal Conjugate Vaccine

Showing 15 of 36 trials with date data

Clinical Trials (36)

Total enrollment: 23,792 patients across 36 trials

Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients

Start: May 2021Est. completion: Apr 2022254 patients
Phase 4Unknown
NCT02492438Pfizer13 valent Pneumococcal Conjugate Vaccine

13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients

Start: Feb 2013Est. completion: Mar 2014154 patients
Phase 4Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Start: Jul 2020Est. completion: Dec 2021694 patients
Phase 3Completed

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

Start: Nov 2019Est. completion: May 2021407 patients
Phase 3Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Start: Sep 2019Est. completion: Aug 20211,184 patients
Phase 3Completed

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

Start: Jun 2019Est. completion: Dec 2020606 patients
Phase 3Completed

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

Start: Jun 2019Est. completion: Mar 20201,205 patients
Phase 3Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Start: Jun 2019Est. completion: Apr 20202,340 patients
Phase 3Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Start: Jan 2019Est. completion: Jun 2020104 patients
Phase 3Completed

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Start: Dec 2018Est. completion: Mar 20212,409 patients
Phase 3Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Start: Sep 2018Est. completion: Nov 2021277 patients
Phase 3Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Start: Jul 2018Est. completion: Jan 20201,515 patients
Phase 3Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Start: Jul 2018Est. completion: Jan 2020302 patients
Phase 3Completed
NCT00980655Pfizer13 valent Pneumococcal Conjugate Vaccine

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Start: Jan 2010Est. completion: May 2013251 patients
Phase 3Completed
NCT00546572Pfizer13 valent Pneumococcal Conjugate Vaccine

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Start: Nov 2007Est. completion: Jul 2010938 patients
Phase 3Completed
NCT00574548Pfizer13 valent Pneumococcal Conjugate Vaccine

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Start: Nov 2007Est. completion: Feb 2010720 patients
Phase 3Completed
NCT00109343Merck & Co.Pneumococcal Conjugate Vaccine

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Start: Mar 2006Est. completion: Sep 20071,027 patients
Phase 3Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Start: Apr 2018Est. completion: Feb 2020460 patients
Phase 2Completed

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Start: Oct 2017Est. completion: May 2019511 patients
Phase 2Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Start: Mar 2017Est. completion: Oct 20181,051 patients
Phase 2Completed

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Start: Oct 2015Est. completion: Jan 2016253 patients
Phase 2Completed

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Start: Oct 2015Est. completion: Jan 2016690 patients
Phase 2Completed
NCT01513551Merck & Co.Pneumococcal Conjugate Vaccine

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Start: Mar 2012Est. completion: Feb 2013692 patients
Phase 2Completed
NCT01215188Merck & Co.Pneumococcal Conjugate Vaccine

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Start: Oct 2010Est. completion: Jul 20121,152 patients
Phase 2Completed

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

Start: Dec 2023Est. completion: May 2026558 patients
Phase 1/2Active Not Recruiting
NCT02531373Merck & Co.V114 Medium Dose

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Start: Sep 2015Est. completion: Apr 2017338 patients
Phase 1/2Completed

Early Versus Delayed Pneumococcal Vaccination in HIV

Start: Sep 2004Est. completion: Oct 200779 patients
Phase 1/2Completed

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

Start: Apr 2023Est. completion: Jun 202490 patients
Phase 1Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)

Start: Apr 2019Est. completion: Jun 2020133 patients
Phase 1Completed

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Start: Aug 2018Est. completion: Mar 2019104 patients
Phase 1Completed

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Start: Nov 2016Est. completion: Aug 201766 patients
Phase 1Completed
NCT01215175Merck & Co.Pneumococcal Conjugate Vaccine

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

Start: Sep 2009Est. completion: Jan 2011150 patients
Phase 1Completed
NCT01444001SanofiPneumococcal Vaccine

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

Start: Feb 2007Est. completion: Aug 200763 patients
Phase 1Completed
NCT04923035Merck & Co.Pneumococcal Conjugate Vaccine

Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation

Start: Oct 2021Est. completion: Dec 20241,010 patients
N/AUnknown
NCT03276754PfizerImmunization To Prevent Acute COPD Exacerbations

Immunization To Prevent Acute COPD Exacerbations

Start: Nov 2017Est. completion: Jun 2022530 patients
N/ATerminated
NCT01899365PfizerAn Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department

An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department

Start: Nov 2015Est. completion: Oct 20171,475 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

12 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space